FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype

被引：38

作者：

Beran, M ^{[1
]}

Luthra, R ^{[1
]}

Kantarjian, H ^{[1
]}

Estey, E ^{[1
]}

机构：

[1] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

LEUKEMIA RESEARCH | 2004年 / 28卷 / 06期

关键词：

Flt3; mutation; diploid AML; chemotherapy outcome; age;

D O I：

10.1016/j.leukres.2003.09.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prognostic impact of FLT3 mutations on the outcome of patients with diploid AML, treated with intensive chemotherapy, was analyzed. In 176 patients, the frequency of single ITD was 30% (<61 years: 37%, >60 years: 23%), single D835 mutation 2.3%, and both 2.3%. There was no association between ITD and CR rate. ITD-positive patients <61 years had a higher frequency of resistant disease. ITD was adversely associated with CR duration and survival in both younger and elderly patients treated with comparable chemotherapy but the effect was less in the elderly. Presence of both ITD and D835 heralded the least favorable outcome. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：547 / 550

页数：4

共 14 条

[1] FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group [J].

Abu-Duhier, FM ;

Goodeve, AC ;

Wilson, GA ;

Gari, MA ;

Peake, IR ;

Rees, DC ;

Vandenberghe, EA ;

Winship, PR ;

Reilly, JT .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) :190-195

[2]

Beran M, 2001, CANCER-AM CANCER SOC, V92, P1999, DOI 10.1002/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO

[3]

2-B

[4]

Boissel N, 2000, BLOOD, V96, p316A

[5] Comparison of idarubicin plus ara-C-, fludarabine plus ara-C-, and topotecan plus ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts [J].

Estey, EH ;

Thall, PF ;

Cortes, JE ;

Giles, FJ ;

O'Brien, S ;

Pierce, SA ;

Wang, XM ;

Kantarjian, HM ;

Beran, M .

BLOOD, 2001, 98 (13) :3575-3583

[6] Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm [J].

Fröhling, S ;

Schlenk, RF ;

Breitruck, J ;

Benner, A ;

Kreitmeier, S ;

Tobis, K ;

Döhner, H ;

Döhner, K .

BLOOD, 2002, 100 (13) :4372-4380

[7] The roles of FLT3 in hematopoiesis and leukemia [J].

Gilliland, DG ;

Griffin, JD .

BLOOD, 2002, 100 (05) :1532-1542

[8]

Kiyoi H, 1999, BLOOD, V93, P3074

[9] The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials [J].

Kottaridis, PD ;

Gale, RE ;

Frew, ME ;

Harrison, G ;

Langabeer, SE ;

Belton, AA ;

Walker, H ;

Wheatley, K ;

Bowen, DT ;

Burnett, AK ;

Goldstone, AH ;

Linch, DC .

BLOOD, 2001, 98 (06) :1752-1759

[10] Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia [J].

Meshinchi, S ;

Woods, WG ;

Stirewalt, DL ;

Sweetser, DA ;

Buckley, JD ;

Tjoa, TK ;

Bernstein, ID ;

Radich, JP .

BLOOD, 2001, 97 (01) :89-94

← 1 2 →